8-OH-DPAT (5-HT1A agonist) Attenuates 6-Hydroxy- dopamine-induced catalepsy and Modulates Inflammatory Cytokines in Rats

Document Type : Original Article


1 Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran

2 Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran 2 Department of Pharmacology and Toxicology, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran

3 Biotechnology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran



Neuroinflammation in Parkinson disease (PD) is associated with glial cells activation and production of different inflammatory cytokines. In this study, we investigated the effect of chronic administration of 8-OH-DPAT on 6-OHDA-induced catalepsy and levels of inflammatory cytokines in cerebrospinal fluid (CSF).
Materials and Methods:
Catalepsy was induced by unilateral infusion of 6-OHDA (8 μg/2 μl/rat) into the central region of the sabstantia nigra pars compacta (SNc) being assessed by the bar-test, 5, 60, 120 and 180 min after intraperitoneal (IP) administration of 8-OH-DPAT (5-HT1A receptor agonist; 0.25, 0.5 and 1mg/kg, IP for 10 days). CSF samples were collected on the tenth day of 8-OH-DPAT administration and analyzed by ELISA method to measure levels of TNF-α, IL-1β and IL-6.
Chronic injection of 8-OH-DPAT decreased catalepsy in a dose dependent manner when compared with the control group. The most anti-cataleptic effect was observed at the dose of 1 mg/kg of 8-OH-DPAT. Levels of TNF-α in CSF increased three weeks after 6-OHDA injection while there was a significant decrease in TNF-α level of parkinsonian animals treated with 8-OH-DPAT (1 mg/kg, IP for 10 days). IL-1β and IL-6 decreased and increased in parkinsonian rats and in 8-OH-DPAT-treated parkinsonian rats, respectively.
Our study indicated that chronic administration of 8-OH-DPAT improves catalepsy in 6-OHDA-induced animal model of PD and restores central concentration of inflammatory cytokines to the basal levels. 5-HT1A receptor agonists can be suggested as potential adjuvant therapy in PD by modulation of cerebral inflammatory cytokines.


1. Hattori N, Sato S. Animal models of Parkinson’s disease: Similarities and differences between the disease and models. Neuropathology 2007; 27:479–483.
2. Bolin LM, Strycharska-Orczyk I, Murray R, Langston JW, Di Monte D. Increased vulnerability of dopaminergic neurons in MPTP-lesioned interleukin-6 deficient mice. J Neurochem 2002; 83:167–175.
3. Di Filippo M, Chiasserini D, Tozzi A, Picconi B, Calabresi P. Mitochondria and the link between Neuroinflammation and Neurodegeneration. J Alzheimers Dis 2010; 20:S369–379.
4. McGeer PL, Itagaki S, Boyes BE, McGeer EG. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 1988;38:1285-1291
5. Tansey MG, McCoy MK, Frank-Cannon TC. Neuroinflammatory mechanisms in Parkinson's disease: Potential environmental triggers, pathways, and targets for early therapeutic intervention. Exp Neurol 2007; 208:1–25.
6. Esposito E, Di Matteo V, Benigno A, Pierucci M, Crescimanno G, Di Giovanni G. Non-steroidal anti-inflammatory drugs in Parkinson's disease. Exp Neurol 2007; 205:295–312.
7. Manthripragada AD, Schernhammer ES, Qiu J, Friis S, Wermuth L, Olsen JH,
et al. Non-steroidal anti-inflammatory drug use and the risk of Parkinson's disease. Neuroepidemiology 2011; 36:155-161.
8. Sawada M, Imamura K, Nagatsu T. Role of cytokines in inflammatory process in Parkinson’s disease. J Neural Transm Suppl 2006; 70:373–381.
9. Tansey MG, Frank-Cannon TC, McCoy MK, Lee JK, Martinez TN, McAlpine FE,
et al. Neuroinflammation in Parkinson's disease: is there sufficient evidence for mechanism-based interventional therapy? Front Biosci 2008; 13:709-717.
10. Nagatsu T, Mogi M, Ichinose H, Togari A. Changes in cytokines and neurotrophins in Parkinson's disease.J Neural Transm Suppl 2000; 60:277-290.
11. Brodacki B, Staszewski J, Toczyłowska B, Kozłowska E, Drela N, Chalimoniuk M,
et al. Serum interleukin (IL-2, IL-10, IL-6, IL-4), TNF_, and INF_ concentrations are elevated in patients with atypical and idiopathic parkinsonism. Neurosci Lett 2008; 441:158–162.
12. Li XZ, Bai LM, Yang YP, Luo WF, Hu WD, Chen JP,
et al. Effects of IL-6 secreted from astrocytes on the survival of dopaminergic neurons in lipopolysaccharide-induced inflammation. Neurosci Res Suppl 2009; 65:252–258.
13. Sawada M, Imamura K, Nagatsu T. Role of cytokines in inflammatory process in Parkinson’s disease. J Neural Transm 2006; 70:373–381.
14. Nayebi MA, Sheidaei H. Buspirone improves haloperidol-induced Parkinson disease in mice through 5-HT
1A receptors. Daru 2010; 18:41-45.
15. Fox SH, Chuang R, Brotchie JM. Serotonin and Parkinson’s disease: On movement, mood, and madness. Mov Disord 2009; 24:1255-1266.
16. Huot P, Fox SH, Brotchie JM. The serotonergic system in Parkinson’s disease. Prog Neurobiol 2011; 95:163–212.
17. Mignon L, Wolf WA. Postsynaptic 5-HT
1A receptor stimulation increases motor activity in the 6-hydroxydopamine-lesioned rat: implications for treating Parkinson’s disease. Psychopharmacology (Berl) 2007; 192:49–59.
18. Riad M, Garcia S, Watkins KC, Jodoin N, Doucet E, Langlois X,
et al. Somatodendritic localization of 5-HT1A and preterminal axonal localization of 5-HT1B serotonin receptors in adult rat brain. J Comp Neural. 2000; 417:181-194.
19. Bibbiani F, Oh JD, Chase TN. Serotonin 5-HT
1A agonist improves motor complications in rodent and primate parkinsonian models. Neurology 2001; 57:1829-1834.
20. Adayev T, El-Sherif Y, Barua M, Penington NJ, Banerjee P. Agonist stimulation of the serotonin1A receptor causes suppression of anoxia-induced apoptosis via mitogen-activated protein kinase in neuronal HN2-5 cells. J Neurochem 1999; 72:1489-1496.
21. Anisman H, Merali Z, Hayley S. Neurotransmitter, peptide and cytokine processes in relation to depressive disorder: Comorbidity between depression and neurodegenerative disorders. Prog Neurobiol 2008; 85:1–74.
22. Sawada H, Hishida R, Hirata Y, Ono K, Suzuki H, Muramatsu S,
et al. Activated microglia affect the nigro-striatal dopamine neurons differently in neonatal and aged mice treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine. J Neurosci Res 2007; 85:1752–1761.
23. Bick RJ, Poindexter BJ, Kott MM, Liang YA, Dinh K, Kaur B,
et al. Cytokines disrupt intracellular patterns of Parkinson's disease-associated proteins alpha-
8-OH-DPAT and Inflammation in Parkinsonian Rats Sharifi et al
Iran J Basic Med Sci, Vol. 16, No. 12, Dec 2013
synuclein, tau and ubiquitin in cultured glial cells. Brain Res 2008; 1217: 203-212.
24. Paxinos G, Watson C: The rat brain in stereotaxic coordinates. Academic Press, Sydney, 1982.
25. Mahmoudi J, Nayebi AM, Samini M, Reyhani-Rad S, Babapour V. Buspirone improves the anti-cataleptic effect of levodopa in 6-hydroxydopamine-lesioned rats. Pharmacol Rep 2011; 63:908-914.
26. Dupre KB, Eskow KL, Negron G, Bishop C. The differential effects of 5-HT
1A receptor stimulation on dopamine receptor-mediated abnormal involuntary movements and rotations in the primed hemiparkinsonian rat. Brain Res 2007; 1158:135-143.
27. Knobelman DA, Kung HF, Lucki I. Regulation of extracellular concentrations of 5-Hydroxytryptamine (5-HT) in mouse striatum by 5-HT
1A and 5-HT1B receptors. J Pharmacol Exp Ther 2000; 292:1111–1117.
28. Madhavan L, Freed WJ, Anantharam V, Kanthasamy AG. 5-Hydroxytryptamine 1A receptor activation protects against N-methyl-D-aspartate-induced apoptotic cell death in striatal and mesencephalic cultures. J Pharmacol Exp Ther 2003; 304:913-923.
29. Dupre KB, Eskow KL, Barnum CJ, Bishop C. Striatal 5-HT
1A receptor stimulation reduces D1 receptor-induced dyskinesia and improves movement in the hemiparkinsonian rat. Neuropharmacology 2008; 55:1321–1328.
30. Bezard E, Gerlach I, Moratalla R, Gross CE, Jork R. 5-HT
1A receptor agonist-mediated protection from MPTP toxicity in mouse and macaque models of
Parkinson’s disease. Neurobiol Dis 2006; 23:77 – 86.
31. Raymond JR, Mukhin YV, Gelasco A, Turner J, Collinsworth G, Gettys TW,
et al. Multiplicity of mechanisms of serotonin receptor signal transduction. Pharmacol Ther 2001; 92:179-212.
32. Charkhpour M, Nayebi AR, Doustar Y, Hassanzadeh K. 8-OH-DPAT prevents morphine-induced apoptosis in rat dorsal raphe nucleus: A possible mechanism for attenuating morphine tolerance. Anesth Analg 2010; 111:1316-1321.
33. Nagatsu T. Parkinson’s disease: changes in apoptosis-related factors suggesting possible gene therapy. J Neural Transm 2009; 109:731–745.
34. Qin L, Wu X, Block ML, Liu Y, Breese GR, Hong JS,
et al. Systemic LPS Causes Chronic Neuroinflammation and Progressive Neurodegeneration. Glia 2007; 55:453-462.
35. Shadrina MI, Slominsky PA, Limborska SA. Molecular mechanisms of pathogenesis of parkinson’s disease. Int Rev Cell Mol Biol 2010; 281:229-266.
36. Hirsch EC, Hunot S. Neuroinflammation in Parkinson’s disease: a target for neuroprotection? Lancet Neurol 2009; 8:382–397.
37. Imamura K, Hishikawa N, Ono K, Suzuki H, Sawada M, Nagatsu T,
et al. Cytokine production of activated microglia and decrease in neurotrophic factors of neurons in the hippocampus of Lewy body disease brains. Acta Neuropathol 2005; 109:141–150.
38. Shaftel SS, Griffin WS, O'Banion MK. The role of interleukin-1 in neuroinflammation and Alzheimer disease: an evolving perspective. J Neuroinflammation 2008; 5:7.